Journal of the American College of Cardiology

Journal of the American College of Cardiology
Audio Summaries

Every issue of Journal of the American College of Cardiology moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.

70 audio summariesNLM Catalog

Specialties

Journal of the American College of Cardiology covers research in these specialties.

Recent summaries

The latest articles summarized from Journal of the American College of Cardiology.

Lipid-Lowering Strategies in the Era of Early Atherosclerosis Detection: 2026 ACC Scientific Statement: A Report of the American College of Cardiology.

Nov 20, 2026

This ACC Scientific Statement asks whether lipid-lowering should begin earlier and continue longer, based on the idea that ASCVD develops from cumulative LDL cholesterol exposure over a lifetime. The authors review epidemiologic, genetic, imaging, and trial evidence, concluding that greater and longer-lasting LDL reduction lowers events, though direct evidence in younger, low-short-term-risk adults is limited. They recommend individualized, shared decision-making that integrates short- and long-term risk, risk enhancers, and, when appropriate, subclinical atherosclerosis imaging, while noting that screening thresholds, safety, adherence, and cost-effectiveness still require study.

Intravascular Lithotripsy vs Super-High-Pressure Noncompliant Balloons for Treatment of Calcified Coronary Lesions: The VICTORY Trial.

Nov 18, 2026

The VICTORY trial asked whether super-high-pressure noncompliant balloons (SH-NCBs) are as effective as intravascular lithotripsy (IVL) for preparing heavily calcified coronary lesions before stenting. In this randomized, open-label noninferiority trial of 278 patients using optical coherence tomography, SH-NCBs achieved noninferior stent expansion (85% vs 84%) with similar procedural success and comparable safety, including coronary perforation rates. Target vessel failure at 30 days was numerically lower with SH-NCBs (2.8% vs 5.7%), though this difference was not statistically significant.

Outcomes of Transcatheter Aortic Valve Replacement for Aortic Regurgitation in LVAD Patients: The JENA-VAD Study.

Nov 17, 2026

The JENA-VAD study asked whether the AR-specific Trilogy transcatheter valve can safely and effectively treat aortic regurgitation in patients with left ventricular assist devices, a population with few options beyond high-risk surgery. In 50 patients, technical and device success was 96%, early safety freedom was 90%, and there were no strokes, MIs, or moderate/severe residual AR at early follow-up. However, leaflet thickening or thrombosis was detected in 22% of patients who had imaging (a likely underestimate, since most patients were not imaged), indicating that longer-term valve durability and thrombosis risk still need to be defined.

10-Year Outcomes of Initial CTO-PCI vs No CTO-PCI Strategies for Chronic Total Occlusion: The DECISION-CTO Randomized Trial.

Nov 16, 2026

The DECISION-CTO trial asked whether an initial strategy of percutaneous coronary intervention for chronic total occlusion (CTO-PCI), compared with no CTO-PCI while both groups received guideline-directed medical therapy, improves long-term outcomes. At 10 years among 804 randomized patients, the composite of death, myocardial infarction, stroke, or any revascularization occurred in 33.9% of the CTO-PCI group versus 37.4% of the no CTO-PCI group, a non-significant difference (P = 0.32). Because the confidence intervals were wide and all-cause mortality also did not differ significantly (12.7% vs 16.5%), the authors conclude that neither benefit nor harm of an initial CTO-PCI strategy can be definitively established.

Angiography-Derived vs Wire-Based Fractional Flow Reserve to Guide Revascularization: The Randomized LIPSIA-STRATEGY Trial.

Nov 14, 2026

The LIPSIA-STRATEGY randomized trial asked whether wire-free angiography-derived vessel FFR (vFFR)-guided revascularization is noninferior to wire-based FFR for intermediate coronary stenoses. At 1 year, MACE occurred in 3.0% of vFFR patients versus 4.1% of FFR patients, meeting the prespecified absolute noninferiority margin. However, because the event rate was lower than expected, the relative margin was less strict than intended, and a post hoc analysis using the originally implied relative margin did not confirm noninferiority in the modified intention-to-treat population, while the per-protocol analysis did.

Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation: Navigating Heterogeneity in Clinical Evidence: JACC Evidence Review.

Nov 12, 2026

This JACC Evidence Review asks whether the recent randomized trials of left atrial appendage closure (LAAC; OPTION, CLOSURE-AF, CHAMPION-AF, and others) can be pooled into a single estimate of LAAC versus anticoagulation for stroke prevention in atrial fibrillation. The authors conclude that these trials differ too much in patient phenotype, comparator, device generation, antithrombotic regimens, endpoint construction, and follow-up to form one coherent evidence base, so pooled estimates may not apply to a common patient group. They therefore recommend anticoagulation as first-line for most eligible patients, with LAAC reserved for those in whom long-term anticoagulation is unsafe or unsustainable, guided by shared decision-making.

Left Atrial Appendage Closure in Patients Considered Unsuitable for Oral Anticoagulation: Randomized Outcomes Through 5 Years in ASAP-TOO.

Nov 12, 2026

The ASAP-TOO trial asked whether left atrial appendage closure (LAAC) with the Watchman device is a safe and effective alternative to standard antithrombotic care in atrial fibrillation patients who are deemed unsuitable for oral anticoagulation. In this prematurely terminated, underpowered randomized trial of 481 patients, LAAC was successfully implanted in 97.8% of attempts and showed a numerically lower rate of ischemic stroke or systemic embolism over up to 5 years (7.8% vs 11.4%, not statistically significant), but major bleeding was higher, particularly in the first 3 months, likely due to the mandated antiplatelet regimen. The authors conclude that these exploratory findings are imprecise and should be interpreted cautiously alongside contemporary evidence and shared decision-making.

Antithrombotic Therapy Management After Left Atrial Appendage Closure: Current Regimens, Evolving Evidence, and the Control Group Dilemma.

Nov 12, 2026

This review examines which antithrombotic regimen is best after percutaneous left atrial appendage closure (LAAC), weighing the need to prevent device-related thrombosis (DRT) against the bleeding risk and the loss of benefit from avoiding long-term oral anticoagulation. The authors appraise evidence from small, heterogeneous trials (ANDES, ADALA) and a meta-analysis favoring DOAC over DAPT for lower DRT, and they note that current guideline regimens rest largely on device-specific protocols or low-certainty evidence. They propose a risk-tailored framework: intensify therapy early for device healing, reassess at 45 to 90 days to de-escalate, continue OAC or DAPT only for concomitant indications, and generally use OAC for definite or probable DRT, without basing decisions on the peridevice leak alone.

Left Atrial Appendage Closure in Atrial Fibrillation Patients With High Risk of Stroke and Bleeding: An Individual Participant Data Meta-Analysis of Randomized Trials.

Nov 12, 2026

This individual participant data meta-analysis of CLOSURE-AF and PRAGUE-17 (1,290 high-risk AF patients) asked whether percutaneous left atrial appendage closure (LAAC) outperforms contemporary medical therapy in patients at high risk of both stroke and bleeding. No significant differences were found for the composite efficacy outcome (21.9% vs 20.7%; adjusted HR 0.98) or major bleeding (adjusted HR 1.03), though major bleeding risk varied over time, being higher with LAAC early (absolute difference 3.4 points at 1 year) and similar by 3 years (1.1 points), so no cumulative bleeding benefit was demonstrated. Longer-term randomized data are needed to clarify later treatment effects.

Comparison of Outcomes Between Men and Women Treated With Left Atrial Appendage Closure or Oral Anticoagulation After Catheter Ablation for Atrial Fibrillation: An OPTION Subanalysis.

Nov 12, 2026

This prespecified sex-based subanalysis of the OPTION trial asked whether left atrial appendage closure (LAAC) and oral anticoagulation (OAC) differ in efficacy and safety for men and women with AF after catheter ablation. In 1,599 patients, neither stroke, systemic embolism, nor death differed between strategies in either sex, but LAAC reduced major/clinically relevant nonmajor bleeding significantly in men (HR 0.34) and only nonsignificantly in women (HR 0.68), with a significant treatment-by-sex interaction (P = 0.02). These findings suggest the bleeding benefit of LAAC over OAC after ablation may be greater in men than in women.

Listen to Journal of the American College of Cardiology

14-day free trial. Every new article, summarized in ~3 minutes.